Semax: The Soviet-Era Neuropeptide Designed for Soldiers That Became Russia's Go-To Brain Drug

The short version

Semax is a synthetic seven-amino-acid peptide originally commissioned by the Soviet Ministry of Defense in 1979. It’s been a registered medicine in Russia since the mid-1990s and was placed on Russia’s List of Vital & Essential Drugs in 2011.
A 2018 meta-analysis of 8 clinical studies (654 patients) found Semax improved neurological outcomes and functional recovery in ischemic stroke patients.
A single intranasal dose increases BDNF protein by 1.4x and BDNF mRNA by 3x in the hippocampus — within hours. Effects last 20-24 hours despite the peptide itself clearing in minutes.
Despite deriving from the stress hormone ACTH, Semax does not raise cortisol. The hormonal activity was specifically engineered out.
Two formulations exist in Russia: 0.1% nasal drops for cognitive enhancement (~50 mcg/drop) and 1% drops for stroke and serious neurological conditions (~500 mcg/drop).
The popular modified variant N-Acetyl Semax Amidate (NASA) has zero clinical studies — and one study found that acetylation actually abolishes a key neuroprotective mechanism (copper chelation).
Not FDA-approved. Not available by prescription outside Russia. Almost all clinical data comes from Russian institutions.

A brain drug born from the Cold War

Most nootropics have boring origin stories. Someone synthesized a molecule, tested it in mice, and a supplement company started selling it.

Semax has a different story.

In 1979, the Soviet Ministry of Defense commissioned a research program at the Institute of Molecular Genetics in Moscow. The assignment: design a peptide that could enhance cognitive performance and protect the brain under extreme stress — without the side effects of existing stimulants. The scientists leading the project were Igor Ashmarin, a neurochemist at Moscow State University, and Nikolay Myasoedov at the Institute of Molecular Genetics.

Their starting point was ACTH — adrenocorticotropic hormone, the stress hormone that triggers cortisol release. Scientists had known since the 1960s that fragments of ACTH could improve memory and attention in animals, independent of any hormonal effects. The problem was that these fragments broke down in the blood within minutes and, depending on the fragment, could still trigger unwanted hormonal responses.

Ashmarin and Myasoedov’s solution was elegant. They took the ACTH(4-7) fragment — the four amino acids responsible for the cognitive effects — and attached a Pro-Gly-Pro tripeptide tail. This tail served two purposes: it dramatically slowed enzymatic degradation, and it had its own independent neuroprotective properties. The result was a peptide that kept the brain benefits of ACTH while completely eliminating the cortisol response.

They named it Semax.

By 1997, after nearly two decades of research, Ashmarin and Myasoedov published a landmark review summarizing their work. The conclusion: Semax “is capable of stimulating operative memory and attention, increasing resistance to hypoxia, and improving brain circulation” — and “in no case did it produce negative side actions or complications” [PMID: 9173745].

Semax received pharmaceutical registration in Russia in the 1990s, was adopted for clinical use in stroke treatment, and in 2011 was placed on the Russian Federation’s List of Vital & Essential Drugs — the highest regulatory endorsement in Russian medicine. The developers received the Russian Government Prize in 2001.

How it works — the simple version

Here’s the basic picture. You spray Semax into your nose. Within minutes, it crosses into your brain. Once there, it does three things that matter:

1. It floods your brain with growth factors.

BDNF (brain-derived neurotrophic factor) is one of the most important molecules for learning, memory, and neuroplasticity. It’s essentially fertilizer for your neurons. A single dose of Semax increases BDNF protein by 1.4x and BDNF mRNA by 3x in the hippocampus — the brain’s memory center. It also doubles the expression of TrkB, the receptor that BDNF binds to [PMID: 16996037].

For context, exercise is one of the most reliable ways to increase BDNF naturally. Semax produces comparable or larger increases, and it does so within hours.

2. It protects neurons from damage.

When brain cells are starved of oxygen (during a stroke, for example), they flood with calcium and glutamate, triggering a toxic cascade that kills neurons. Semax counteracts this at multiple levels — it suppresses inflammatory signaling, activates recovery pathways (CREB), and downregulates cell-death machinery (JNK, MMP-9) [PMID: 34201112].

It also chelates copper ions with extraordinary affinity, preventing copper-mediated amyloid-beta aggregation — a process central to Alzheimer’s disease [PMID: 35080861].

3. It modulates mood and focus without being a stimulant.

Semax doesn’t directly increase dopamine. Instead, it sensitizes dopaminergic circuits — priming them to respond more effectively. It increases serotonin turnover by up to 180% in the striatum. And it enhances GABA signaling by 147% in certain brain regions while reducing glycine currents, creating what researchers describe as a “balanced” excitatory-inhibitory shift [PMID: 29577196, PMID: 16362768].

The net effect, based on both clinical and user reports: improved focus, verbal fluency, and reduced anxiety — without the jitteriness of stimulants or the sedation of anxiolytics.

What Russian doctors use it for

Semax is prescribed in Russia as intranasal drops in two concentrations:

0.1% solution (~50 mcg per drop) — the nootropic formulation:

Memory and attention deficits
Cognitive decline in elderly patients
Recovery from mild traumatic brain injury
Asthenic conditions (mental fatigue, burnout)
Optic nerve diseases (glaucoma, optic atrophy)

1% solution (~500 mcg per drop) — the neurological formulation:

Acute ischemic stroke (within first 12 hours, up to 12,000 mcg/day)
Dyscirculatory encephalopathy (chronic cerebrovascular disease)
Post-operative recovery after neurosurgery
Transient ischemic attacks

Standard nootropic dosing is 200-600 mcg per day (2-3 drops of 0.1% in each nostril, 2-3 times daily) for courses of 10-14 days. Stroke protocols use the 1% solution at much higher doses — 6,000-12,000 mcg/day for 5-14 days.

The prescribing information notes that effects persist for 20-24 hours after administration, despite the peptide itself being cleared from the blood within minutes. This is because Semax triggers downstream gene expression changes (BDNF, NGF, and dozens of other genes) that outlast the molecule itself.

The clinical evidence

The meta-analysis — 654 patients

The strongest single piece of evidence for Semax is a 2018 meta-analysis published in the Bulletin of Rehabilitation Medicine, pooling data from 8 clinical studies totaling 654 patients with ischemic stroke. The analysis found that Semax treatment was associated with improved NIHSS (neurological deficit) scores and better functional outcomes compared to standard treatment alone.

This is significant because meta-analyses sit at the top of the evidence hierarchy. However, the authors themselves called for “proper multicenter double-blind RCTs” — acknowledging that the individual studies pooled had methodological limitations.

The 110-patient stroke trial

The largest individual Semax trial was a 2018 prospective study by Gusev et al. in 110 patients with acute ischemic stroke [PMID: 29798983].

Semax 6,000 mcg/day intranasally during stroke rehabilitation
The treatment group showed significantly increased plasma BDNF levels — confirming the mechanism seen in animal studies translates to humans
Functional recovery on the Barthel Index was significantly better in the Semax group
Motor performance improved more than in the rehabilitation-only group

Cognitive enhancement in healthy adults

A crossover study tested Semax in healthy volunteers and found improved attention and working memory performance. A separate fMRI study (n=24) showed that Semax altered functional brain network connectivity in patterns associated with enhanced cognitive processing.

Optic nerve disease

Two clinical studies examined Semax for optic nerve conditions. In a double-blind, placebo-controlled study in glaucoma patients, Semax improved visual acuity and visual field parameters. A second study in patients with optic nerve atrophy showed similar benefits.

These eye studies are noteworthy because the optic nerve is an extension of the brain — neuroprotective effects that work in the brain should theoretically work in the retina and optic nerve too. The data suggests they do.

Pediatric ADHD

A randomized controlled trial studied 78 children with ADHD across three arms: Semax, piracetam, and placebo. This is one of the rare Semax studies with a true placebo control. The study found improvements in attention parameters in the Semax group. Details beyond this summary are available only in Russian.

Other clinical uses

Semax has also been studied clinically for:

Peptic ulcer disease (n=89.5% vs 30.8% healing rate compared to control)
Post-anesthesia cognitive recovery
Atopic dermatitis (patented use in Russia: RU2347582C1)
Adaptogenic effects under physical stress (military/sports performance)

The Semax + Selank stack

If you’ve looked into Semax at all, you’ve encountered the Semax + Selank combination. It’s the most discussed nootropic peptide stack in biohacking communities, and the pairing isn’t random — these two peptides were developed at the same institution (Institute of Molecular Genetics, Moscow) and are designed to complement each other.

Semax = cognitive activation, BDNF upregulation, focus, neuroprotection Selank = anxiolytic, GABA modulation, emotional stability, stress reduction

The logic: Semax provides the cognitive drive; Selank smooths out the edges. One accelerates, the other stabilizes.

Here’s the honest caveat: no clinical study has ever tested the combination. The rationale is pharmacologically sound (different mechanisms, complementary effects), and the community experience is consistently positive. But “makes sense and people like it” is not the same as “clinically proven.” Until a study actually tests the stack, we’re working with theory and anecdote.

The modified variants — what the evidence actually shows

Three modified versions of Semax circulate in the nootropic market:

N-Acetyl Semax — An acetyl group is added to the N-terminus for improved stability. Limited data suggests 2-3x potency compared to standard Semax.

N-Acetyl Semax Amidate (NASA) — Both acetylation and amidation for maximum stability and blood-brain barrier penetration. Reported to be 3-5x more potent with effects lasting 6-12 hours. Zero published clinical studies. All claims are extrapolated from standard Semax data or are purely anecdotal.

Adamax — The newest variant, adding an adamantyl group. Has existed for approximately 2 years. Zero peer-reviewed evidence of any kind.

And here’s the finding that NASA enthusiasts won’t like: a 2016 study examined what happens when you acetylate Semax’s N-terminus. The acetylation altered copper coordination geometry and — critically — abolished the cellular protective effect against copper-mediated toxicity [PMID: 27586814]. The free NH2 terminus turns out to be essential for one of Semax’s key neuroprotective mechanisms.

This doesn’t mean NASA is useless. It may retain the BDNF and dopaminergic effects. But the claim that it’s “strictly superior” to standard Semax is not supported by the evidence. You may be gaining stability while losing neuroprotection. Nobody knows for sure because nobody has studied it.

Safety

Across all published Semax studies — clinical and preclinical — no serious adverse events have been reported. The 1997 landmark review covering 15 years of research stated flatly: “in no case did it produce negative side actions or complications.”

Commonly reported side effects (mild):

Nasal irritation or dryness (intranasal use)
Mild headache
Dizziness (rare)

From the Russian prescribing information:

Contraindicated in pregnancy and breastfeeding
Use with caution in patients with endocrine disorders — one study found 7.4% of patients showed mild glucose elevation
No drug dependence or withdrawal documented
No organ toxicity in chronic use

What we don’t have:

Long-term safety data from controlled Western studies
Drug interaction data with Western psychiatric medications (SSRIs, stimulants) — caution warranted
Post-marketing pharmacovigilance reports (same gap as Noopept)

WADA status: Semax is NOT on the WADA prohibited list, unlike many other peptides (BPC-157, TB-500, growth hormone secretagogues).

The honest limitations

The Russian evidence concentration. Virtually all clinical data comes from Russian institutions, many affiliated with the Institute of Molecular Genetics where Semax was developed. No independent Western clinical trials have been conducted. Russian Wikipedia itself flags Semax among “medicines with unproven effectiveness.”

No large-scale Western-standard RCTs. The meta-analysis pooled 654 patients, which is meaningful, but the individual studies had methodological limitations. No multicenter, double-blind, placebo-controlled trial of the size Western regulators require has been conducted.

Potential conflicts of interest. Myasoedov, the co-developer, is an author on the majority of Semax publications. The manufacturer (Peptogen) has connections to the research institutions. This is common in Russian pharmaceutical development but is a legitimate concern for evidence evaluation.

Mechanism is not fully understood. Despite 200+ papers, there is no single identified receptor or pathway that explains all of Semax’s effects. The honest answer from the scientific community: it works through multiple convergent mechanisms, and we don’t have the complete picture.

Quality outside Russia is unreliable. Third-party testing of research-grade Semax from non-Russian vendors has found some products contain only 40-60% of the labeled dose. If you’re not getting it from a Russian pharmacy, you may not be getting what was studied in clinical trials.

What this means for you

Semax has more clinical evidence than most nootropics — a meta-analysis, multiple clinical trials across stroke, cognition, ophthalmology, and pediatrics, plus a 30+ year track record in Russian clinical practice.
But it falls short of Western regulatory standards. No FDA-approved use, no large-scale Western RCTs, no independent replication outside Russia.
If you try it, use the standard formulation first. The 0.1% nasal drops at 200-600 mcg/day is what was actually studied. Don’t start with NASA or Adamax — there’s no clinical data on those.
Source matters enormously. Russian pharmaceutical-grade Semax (from vendors like CosmicNootropic or RUPharma that ship actual Russian pharmacy products) is a different product than research-grade peptide reconstituted from lyophilized powder.
The combination with Selank is pharmacologically rational but clinically untested. If you stack them, try each one alone first so you know what’s doing what.
Consult a healthcare professional — especially if you’re on psychiatric medications, have endocrine disorders, or have a history of stroke.

What’s next for Semax

Semax sits in an interesting position. It has genuine clinical utility for stroke recovery — enough that Russia put it on their essential drugs list. The BDNF data is among the most robust for any nootropic compound. And the Cold War origin story makes it one of the few peptides with a legitimate development narrative rather than a marketing one.

What it needs is what every promising Russian peptide needs: independent Western clinical trials with proper methodology, adequate sample sizes, and no conflicts of interest. The 2018 meta-analysis authors said it plainly. Until that happens, Semax remains one of the most evidence-backed nootropics available — in a field where that bar is frustratingly low.

Sources

Ashmarin I.P. et al. A nootropic ACTH analog semax (15 years of design and study). Zh Vyssh Nerv Deiat. 1997;47(2):420-30. PMID: 9173745
Gusev E.I. et al. Semax in stroke: efficacy and BDNF elevation. Zh Nevrol Psikhiatr. 2018. PMID: 29798983
Dolotov O.V. et al. Semax binds specifically and increases BDNF in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-6. PMID: 16635254
Dolotov O.V. et al. Semax regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PMID: 16996037
Shadrina M. et al. Temporal dynamics of NGF and BDNF expression under Semax. J Mol Neurosci. 2010;41(1):30-5. PMID: 19662538
Filippenkov I.B. et al. Semax affects immune and vascular gene expression in rat brain ischemia. BMC Genomics. 2014;15:228. PMID: 24661604
Filippenkov I.B. et al. Semax protein expression profile confirms neuroprotection in ischemia. Int J Mol Sci. 2021;22(12):6179. PMID: 34201112
Eremin K.O. et al. Semax activates dopaminergic and serotoninergic brain systems. Neurochem Res. 2005;30(12):1493-500. PMID: 16362768
Sciacca M.F.M. et al. Semax affects copper-induced amyloid-beta aggregation. ACS Chem Neurosci. 2022;13(4):486-496. PMID: 35080861
Magri A. et al. Semax N-terminus acetylation abolishes copper chelation neuroprotection. J Inorg Biochem. 2016;164:59-69. PMID: 27586814
Sharonova I.N. et al. Modulation of GABA and glycine currents with Semax. Bull Exp Biol Med. 2018;164(5):612-616. PMID: 29577196
Sebentsova E.A. et al. Semax and haloperidol dopaminergic interaction. Bull Exp Biol Med. 2006;141(2):170-4. PMID: 16984088
Kost N.V. et al. Semax and Selank inhibit enkephalin-degrading enzymes. Bioorg Khim. 2001;27(3):180-3. PMID: 11443939
Dmitrieva V.G. et al. Semax and PGP activate neurotrophin transcription after ischemia. Cell Mol Neurobiol. 2010;30(1):71-9. PMID: 19633950
Potaman V.N. et al. N-terminal degradation of ACTH(4-10) and Semax. Biochem Biophys Res Commun. 1991;176(2):741-6. PMID: 1851003
Firstova Y.Y. et al. Nootropic drugs and hippocampal/cortical BDNF in mice. Eksp Klin Farmakol. 2009;72(6):3-6. PMID: 20095391
2018 Meta-analysis of Semax in ischemic stroke. Bulletin of Rehabilitation Medicine. 8 studies, n=654.
Pediatric ADHD RCT (n=78, Semax vs piracetam vs placebo). Russian-language publication.
Double-blind glaucoma study. CyberLeninka: https://cyberleninka.ru/article/n/rezultaty-issledovaniya-neyroprotektornoy-effektivnosti-preparata-semaks
Semax development history. https://semax.ru/chto_eto/istorija/
Semax prescribing information (0.1%). https://www.vidal.ru/drugs/semax__28676
Semax prescribing information (1%). https://www.rlsnet.ru/tn_index_id_5678.htm
Russian Patent RU2157258C1 — Optic nerve treatment. https://patents.google.com/patent/RU2157258C1/ru
Russian Patent RU2347582C1 — Atopic dermatitis. https://patents.google.com/patent/RU2347582C1/ru
Semax and Selank GABAA receptor comparison. Neurochemical Journal. 2021. https://link.springer.com/article/10.1134/S1819712421030120
Semax/Selank route of administration comparison. Neurochemical Journal. 2020. https://link.springer.com/article/10.1134/S1819712420030113
CyberLeninka — Adaptogenic activity of Semax and Selank. https://cyberleninka.ru/article/n/adaptogennaya-aktivnost-semaksa-i-selanka-eksperimentalnoe-issledovanie
Semax Wikipedia (Russian). https://ru.wikipedia.org/wiki/Семакс
ResearchGate — Stroke efficacy. https://www.researchgate.net/publication/325375504
Integrative Physiology — Comprehensive Semax review. https://intphysiology.ru/index.php/main/article/view/163